AdvanCell

AdvanCell is a clinical stage radiopharmaceutical company with the slogan "Changing the Course of Cancer Treatment". Founded in 2019 and headquartered in Australia, AdvanCell focuses on developing a pipeline of 212Pb-based Targeted Alpha Therapies for cancer patients. The company's platform technology addresses a major challenge in Targeted Alpha Therapy by ensuring a reliable and scalable supply of isotope. Leveraging daily access to 212Pb, considered the ideal isotope for Targeted Alpha Therapy, AdvanCell's novel drug discovery and preclinical processes, along with its state-of-the-art facilities, demonstrate promise in advancing cancer treatment. Despite limited information on the last investment and investors, AdvanCell's innovative approach to cancer treatment positions it as a noteworthy player in the Biotechnology and Pharmaceutical industries. Learn more at www.advancell.com.au.